Cydar are proud supporters of BSET (British Society of Endovascular Therapy)
We have a vision of a world where all surgery works exactly as planned.
We started in 2012, founded by a vascular surgeon and imaging scientist frustrated by the difficulty surgeons had visualising 'image guided' procedures and the resulting inconsistency of patient care. Since then, our team has been dedicated to building a future where all patients benefit from augmented surgical intelligence.
Find out about our incredible team that is working together to revolutionise surgical knowledge and patient care.
Chief Executive Officer
Paul has more than 20 years of business growth and scaling experience. He was latterly a key member of the executive team at BTG plc, which was acquired in 2019 by Boston Scientific. Paul had a wide-ranging role at BTG, as General Counsel & Head of Strategic Affairs and also managing director of both BTG’s IP licensing business as well as one of BTG’s small MedTech business units. Paul has been an advisor to the boards of a range of healthcare businesses, previously held a variety of corporate finance roles, and has a PhD. in Biotechnology.
Executive Director and Co-Founder
Tom was appointed a consultant vascular surgeon in 2004. Specialising in minimally-invasive endovascular surgery, he established the complex aortic programme at Guy’s and St Thomas’ Hospitals in London and embarked on the research partnership with Graeme Penney that led to the founding of Cydar.
Chief Scientific Officer and Co-Founder
Graeme has over 25 years' experience as a research scientist investigating the use of image registration to aid minimally invasive surgery. He has published extensively in the field of 2D-3D image registration and is co-inventor on a number of patents in this field. While working as a Senior Lecturer at King’s College London he worked with Tom Carrell on methods to improve visualisation during endovascular surgery. This research led to the founding of Cydar.
Chief Financial Officer
Helen is an experienced finance professional having worked in the Cambridge high growth sector for fifteen years. Prior to joining us, she worked for a number of companies including start-ups and public companies in senior finance roles. She is a chartered accountant and fellow of the ICAEW having trained and qualified with Deloitte.
Chief Technology Officer
Rob brings over 15 years of experience in both research and product development, ranging from user interfaces and ubiquitous computing to low-level application infrastructure and algorithm implementation.
Paul is an experienced International Sales and Marketing Professional with over 18 years in the medical device industry. He has previously held leadership roles with Oxford Medtech, Lombard Medical and Boston Scientific, directing the strategic & operational commercial business across Europe, Asia-Pacific and Latin America.
Lord Davies of Abersoch
Lord Mervyn Davies brings commercial and international experience to the Board as both a former CEO and Chairman of Standard Chartered Bank, former Minister for Trade, Investment, Small Business and Infrastructure and as current Chairman of Corsair Capital and a Director across a diverse range of companies.
John E. Deanfield
Professor Deanfield brings expertise in cardiovascular imaging, large-scale clinical trials and outcomes research, both nationally and internationally. He is Professor of Cardiology at University College London and Director of the National Institute for Cardiovascular Outcomes Research (NICOR).
Mark Evans is co-founder and CEO of Adaptix Ltd and co-founder and former Chairman of Mirada Medical, both UK medical imaging companies. Mark brings expert knowledge and experience of the global medical imaging sector and a strong network within the domain.
James B. Downing
James Downing brings extensive deal structuring and negotiating skills as a corporate finance specialist, and former Deputy Head of European Investment Banking at JP Morgan Chase & Co and currently as Non-Executive Director on a number of companies.
Franz B. Humer
Dr Franz B. Humer brings a wealth of healthcare and commercialisation experience as well as deep insights into clinical applications and health data. He is former CEO and Chairman of Roche Plc, having previously been at Glaxo and Schering Plough.
A qualified chartered accountant Marek spent 25 years in Private Equity executing over £8bn of transactions across a variety of sectors, geographies, and economic cycles. He co-founded 24 Haymarket in 2012 which focusses on investing in startups. He sits on a number of boards advising on strategy, financial reporting, and fundraising.